Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
CTX130（一种靶向CD70的同种异体CRISPR-Cas9基因编辑CAR T细胞疗法）在复发或难治性T细胞恶性肿瘤患者中的安全性和活性（COBALT-LYM）：一项单臂、开放标签、1期剂量递增研究
期刊:Lancet Oncology
影响因子:35.9
doi:10.1016/S1470-2045(24)00508-4
Iyer, Swaminathan P; Sica, R Alejandro; Ho, P Joy; Prica, Anca; Zain, Jasmine; Foss, Francine M; Hu, Boyu; Beitinjaneh, Amer; Weng, Wen-Kai; Kim, Youn H; Khodadoust, Michael S; Huen, Auris O; Williams, Leah M; Ma, Anna; Huang, Elaine; Ganpule, Avanti; Nagar, Shashwat Deepali; Sripakdeevong, Parin; Cullingford, Erika L; Karnik, Sushant; Dequeant, Mary-Lee; Patel, Janki N; He, Xinyi Shirley; Li, Ziliang; He, Qiuling Ally; Mendonez, Joy H; Keegan, Alissa; Horwitz, Steven M
肿瘤
CD7
T细胞
肿瘤免疫
CD70
T细胞
细胞生物学
免疫/内分泌
